To date, the RET-targeted inhibitor selpercatinib (LOXO-292) is FDA-approved for the treatment of patients ≥ 12 years of age with metastatic RET-mutant medullary thyroid cancer who require systemic therapy and adult patients with metastatic RET fusion-positive NSCLC17, its clinical effect in patients with above three mutant PCPG remains unknown. This evidence concerns the gene RET and medullary thyroid gland carcinoma.